WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, ... Financials. Revenues for the three and twelve months ended December 31, 2024 were $2.0 million and $94.6 million ... WebApr 10, 2024 · Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. About the company Rewards Revenue is forecast to grow 46.65% per year Risk Analysis Negative shareholders equity
Cytokinetics Inc. Financials CYTK Barron
Web18 hours ago · Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 04/03/23-4:00PM EST GlobeNewswire 3 Best Stocks to Buy Now, 4/3/2024, According to Top Analysts WebApr 5, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media. Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. optus ashfield opening hours
Cytokinetics - Wikipedia
WebAug 5, 2024 · SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2024. ... Financials. Revenues for the ... WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2024. Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2024 was $389.0 million or $4.33 per share. WebFeb 17, 2024 · Cytokinetics Financials Summary financials Revenue ( FY, 2024) $94.6M Net income ( FY, 2024) ($389.0M) Cash ( FY, 2024) $65.6M EBIT ( FY, 2024) ($324.2M) … optus apple watch setup